MANGOCEUTICALS, INC. (MGRX)
Mangoceuticals, Inc. dedicates its operations to the creation, promotion, and distribution of a variety of health and wellness products and services specifically designed for men. These offerings are primarily delivered through a telemedicine platform. The company's product line includes treatments for erectile dysfunction, marketed under the 'Mango' brand. Consumers can purchase these items directly from its official online portal, mangorx.com. Established in 2021, Mangoceuticals, Inc. is headquartered in Dallas, Texas, and operates as an affiliate of Cohen Enterprises, Inc.
Sector: Services-Misc Health & Allied Services, NEC
Industry: Medical - Healthcare Information Services
Mangoceuticals, Inc.
NASDAQ:MGRXHealthcare · Medical - Healthcare Information Services
-0.19%$0.1600
CLOSED · Nov 17Prev close$0.1603-0.19%Close$0.1600+3.37%AH close$0.1654
AH$0.1654+3.38%vs close
Mkt Cap$3.56M
EV-
Float17.27M
O/S22.22M
VOL409K sh
$ Vol$65K
RVOL0.52×
Inst Own7.5%
SI0.3%
Net Cash/Sh-
Dilution
MCap$3.56MFloat17.27MO/S22.22M
Dilution
| Form | Description | Links | |
|---|---|---|---|
| DEF 14A | |||
| 10-Q | |||
| 8-K | |||
| 1-A | |||
| 8-K | |||
| PRE 14A | |||
| 8-K | |||
| 424B5 | |||
| 4 | |||
| 4 | |||
| 4 | |||
| 13D/A | |||
| 8-K | |||
| 8-K | |||
| 10-Q | |||
| 425 | |||
| 425 | |||
| 425 | |||
| 8-K | |||
| 425 | |||
| 8-K | |||
| 425 | |||
| S-8 | |||
| 8-K | |||
| 10-Q |
1-25 of 246 filings
…
Recent SEC filings with analysis
- 8-KMangoceuticals entered into a securities purchase agreement on October 8, 2026 for a registered direct offering of 657,000 shares at a combined $0.75 per share…
- 424B5Mangoceuticals (MGRX) is raising ~$475K net via a direct offering of 657,000 shares at $0.75 plus warrants, priced at a ~70% premium to the October 7 close of…
- SCHEDULE 13D/AMangoceuticals' CEO Jacob Cohen and his Tiger Cub Trust filed Amendment No.
- 8-KMangoceuticals (NASDAQ: MGRX) entered subscription agreements for two accredited investors to purchase an aggregate 25% of its subsidiary MangoRx IP Holdings,…